Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with docetaxel and SBRT in PD-(L)1–refractory driver-negative advanced NSCLC
ChiCTR2600122045Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective response rate. Started Apr 2026; status: recruiting.
02
Drugs
iparomlimabtuvonralimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122045.